WILSON JAMES N sold $1.1M of CORT (indirect holdings)

WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.81 ($114.48–$116.30, $1.15M total) across 3 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILSON JAMES N
Published Oct 16, 2026, 10:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale provides fresh, material data that may affect short-term price dynamics for CORT.

02

Market read

Primary insider sale news; modest but actionable for short-term traders monitoring biotech stocks.

03

What to watch

The director's 10b5-1 plan suggests pre-scheduled execution, reducing negative inference.

Relevance 5/10Novelty 7/10Timing: after-hours filing on 2026-10-16

Background

SEC Form 4 filings disclose insider transactions; a director's sale is publicly reported and can influence investor sentiment.

Company-level read

Ticker impact

$CORTBearishHigh confidence
Context

Director Wilson James N sold 10,000 shares for $1.148M via a Form 4 filing, reducing his holdings to 1,054,543 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary source; a $1.1M sale by a director is material and new information.

Market effects

May raise concerns for other biotech stocks if insider selling is viewed as a sector signal.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; primarily relevant to CORT shareholders.

Counterpoint

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Corcept Therapeutics Inc.

    Biopharmaceutical company developing treatments for endocrine disorders.

  • Wilson James N.

    Director of Corcept Therapeutics who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.